Novo Nordisk spokesperson: Regulatory filing for Cagrisema is expected by the end of 2025. We are encouraged by the properties of Cagrisema, which appears safe, well tolerated, and broadly similar to other GLP-1s.
Email Subscription
Newsletters and emails are now available! Delivered on time, every weekday, to keep you up
to date with North American business news.
Weekly Highlights